A Phase II study of cisplatin and cytosine arabinoside for recurrent squamous cell carcinoma of the head and neck

J. I. Bernstein, C. Jacobs, Frederick J Meyers, L. Rich-Goffinet, L. Tanaka

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Based on experimental data suggesting synergy between cisplatin and cytosine arabinoside, 17 patients with recurrent squamous cancer of the head and neck were treated with this combination. The response rate was 18% with no complete responses, and the partial responses were of brief duration. There were moderate hematologic and gastrointestinal toxicities and two therapy-related deaths. The study was stopped early because of low reponse. When compared to results reported for cisplatin alone, the combination of cisplatin and cytosine arabinoside offered no clear advantage.

Original languageEnglish (US)
Pages (from-to)58-60
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume9
Issue number1
StatePublished - 1986
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A Phase II study of cisplatin and cytosine arabinoside for recurrent squamous cell carcinoma of the head and neck'. Together they form a unique fingerprint.

  • Cite this